Ioannis Parodis

Ioannis Parodis

Lecturer, adjunct

Department and organisational affiliation:

About me

  • 2021 (ongoing) - Coordinator for clinical competences in the Curriculum Committee of the Medicine Programme of the Karolinska Institutet
  • 2020 (ongoing) - Director of studies for the elective courses in the Medicine Programme of the Karolinska Institutet
  • 2020 (ongoing) - Member of the Delegation for Education of the Swedish Society of Medicine
  • 2020 (ongoing) - Member of the working group for Interprofessional Learning Environments, Region Stockholm
  • 2019 (ongoing) - Assistant Director of Studies for the Internal Medicine course in the Medicine Programme of the Karolinska Institutet
  • 2018 (ongoing) - Responsible for the elective course "Acute and chronic inflammation", Karolinska Institutet
  • 2018 (ongoing) - Promoter for Interprofessional Education, Karolinska Institutet
  • 2017 (ongoing) - Convener for national working group for rheumatology learning outcomes for undergraduates within the frame of the Swedish Society for Rheumatology
  • 2017 (ongoing) - Responsible for the course for rheumatology residents "Inflammatory systemic diseases", Karolinska Institutet/Karolinska University Hospital
  • 2015 (ongoing) - Responsible for the clinical rotation "Inflammatory diseases" (LINK/ERASMUS), Karolinska Institutet
  • 2015 to 2020 - Responsible for the rheumatology rotation for undergraduates, Karolinska University Hospital

Research description

Clinical and translational research within the field of inflammation and autoimmunity. 

The goal of my research is to contribute to improved surveillance and management for people living with systemic lupus erythematosus. I focus on identification of biomarkers that reflect activity and portend flare, response or non-response to therapy, particularly B cell targeted biologics, and long-term outcome. I stress on patient-reported health status and patient participation in medical care. Last but not least, I am involved in projects within medical pedagogy; we are currently working on the development of a novel virtual patient modality for interprofessional learning.

 

Doctoral education

Systemic lupus erythematosus: biomarkers and biologics

Defence: 17 February 2017

Main supervisor: Iva Gunnarsson

Co-supervisors: Vivianne Malmström, Agneta Zickert, Ronald van Vollenhoven

Opponent: Frédéric Houssiau

 

 

Publication list

 

Peer-reviewed original articles

Submitted; not yet accepted

  • Chalmers S, Rajalakshmi Ramachandran R, Garcia S, Der E, Herlitz L, Ampudia J, Zhang T, Parodis I, Gunnarsson I, Ding H, Shen N, Petri M, Mok C, Saxena R, Polu K, Connelly S, Ng C, Mohan C, Putterman C. The CD6-ALCAM pathway promotes lupus nephritis via T cell mediated responses. [Under review]
  • Hernández-Breijo B, Navarro-Compán V, Plasencia-Rodríguez C, Parodis I, Gehin JE, Martínez-Feito A, Novella-Navarro M, Mezcua A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. [Under review]
  • Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, Enman Y, Lampa J, Parodis I. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. [Under review]
  • Lindblom J, Gomez A, Borg A, Emamikia S, Ladakis D, Matilla J, Pehr M, Enman Y, Heintz E, Regardt M, Parodis I. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. [Revised manuscript under review]

Published/accepted

  • Borg A, Gomez A, Cederlund A, Cobar F, Qiu V, Lindblom J, Emamikia S, Enman Y, Pettersson S, Parodis I. Contribution of abnormal BMI to adverse health-related quality of life outcomes following treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2021 [Epub ahead of print]

https://pubmed.ncbi.nlm.nih.gov/33404659/

  • Parodis I, Vital EM, Hassan S, Jönsen A, Bengtsson AA, Eriksson P, Leonard D, Gunnarsson I, Rönnblom L, Sjöwall C. De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2020 [Epub ahead of print]

https://pubmed.ncbi.nlm.nih.gov/33341888/

  • Gomez A, Hani Butrus F, Johansson P, Åkerström E, Soukka S, Emamikia S, Enman Y, Pettersson S, Parodis I. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2020. doi:10.1093/rheumatology/keaa453 [Epub ahead of print]

https://pubmed.ncbi.nlm.nih.gov/32918459/

  • Parodis I, Gokaraju S, Zickert A, Vanarsa K, Zhang T, Habazi D, Botto J, Serdoura Alves C, Giannopoulos P, Larsson A, Svenungsson E, Gunnarsson I, Mohan C. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2020 Sep 1;59(9):2237-2249

https://pubmed.ncbi.nlm.nih.gov/31722419/

  • Gomez A, Soukka S, Johansson P, Åkerström E, Emamikia S, Enman Y, Chatzidionysiou K, Parodis I. Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. Journal of Clinical Medicine. 2020 Jun 10;9(6)

https://pubmed.ncbi.nlm.nih.gov/32532059/

  • Parodis I, Åkerström E, Sjöwall C, Sohrabian A, Jönsen A, Gomez A, Frodlund M, Zickert A, Bengtsson AA, Rönnelid J, Gunnarsson I. Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2020 May 14;21(10)

https://pubmed.ncbi.nlm.nih.gov/32422945/

  • Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks S, Moroni G, Mosca M, Parodis I, Praga M, Smolen J, Tesar V, Trachana M, van Vollenhoven R, Voskuyl A, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas D. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases. 2020 Mar 27. pii: annrheumdis-2020-216924. doi: 10.1136/annrheumdis-2020-216924

https://pubmed.ncbi.nlm.nih.gov/32220834/

  • Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, Houssiau FA, Tamirou F. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford). 2020; 59: 3424-3434

https://pubmed.ncbi.nlm.nih.gov/32353879/

  • Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019 Dec 1;58(12):2170-2176

https://pubmed.ncbi.nlm.nih.gov/31157891/

  • Sohrabian A#, Parodis I#, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Research and Therapy. 2019 Nov 29;21:259 #Contributed equally

https://pubmed.ncbi.nlm.nih.gov/31783909/

  • Parodis I#, Emamikia S#, Gomez A, Gentline C, Arkema EV, Chatzidionysiou K, van Vollenhoven RF. Evaluation of Definitions Of Remission In Systemic Lupus Erythematosus (DORIS): a post-hoc analysis of two randomised clinical trials. The Lancet Rheumatology. 2019;1(3):e163-e73 #Contributed equally

https://www.thelancet.com/pdfs/journals/lanrhe/PIIS2665-9913(19)30049-9.pdf

  • * Ramsköld D#, Parodis I#, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mikeš J, Achour A, Amara K, Piehl F, Brodin P, Gunnarsson I, Malmström V. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019; 40: 517–527 #Contributed equally

https://pubmed.ncbi.nlm.nih.gov/30593436/

  • Parodis I, Gomez A, Emamikia S, Chatzidionysiou K. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019; 78(7): 1006–1007

https://pubmed.ncbi.nlm.nih.gov/30610063/

  • Parodis I, Emamikia S, Gomez A, Gunnarsson I, van Vollenhoven RF, Chatzidionysiou K. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. Expert Opinion on Biological Therapy. 2019; 19(2): 157–168

https://pubmed.ncbi.nlm.nih.gov/30571926/

  • Parodis I, Ding H, Zickert A, Cosson G, Fathima M, Grönwall C, Mohan C, Gunnarsson I. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. PLoS One. 2019; 14: e0212068

https://pubmed.ncbi.nlm.nih.gov/30742665/

  • Parodis I, Lopez Benavides AH, Zickert A, Pettersson S, Möller S, Welin Henriksson E, Voss A, Gunnarsson I. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care & Research (Hoboken). 2019; 71(6): 811–821

https://pubmed.ncbi.nlm.nih.gov/30055091/

  • Hernández-Breijo B, Gomez A, Soukka S, Johansson P, Parodis I. Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Autoimmunity Reviews. 2019; 18(10): 102372

https://pubmed.ncbi.nlm.nih.gov/31408737/

  • Edelbring S, Parodis I, Lundberg IE. Increasing reasoning awareness: video analysis of students’ two-party virtual patient interactions. Journal of Medical Internet Research (JMIR) Medical Education. 2018; 4: e4

https://pubmed.ncbi.nlm.nih.gov/29487043/

  • Parodis I, Söder F, Faustini F, Kasza Z, Samuelsson I, Zickert A, Svenungsson E, van Vollenhoven RF, Malmström V, Wermeling F, Gunnarsson I. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus. 2018; 27(9): 1470–1478

https://pubmed.ncbi.nlm.nih.gov/29783918/

  • Parodis I, Gomez A, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I. Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opinion on Biological Therapy. 2018; 27(9): 1470–1478

https://pubmed.ncbi.nlm.nih.gov/29958508/

  • * Parodis I, Ding H, Zickert A, Arnaud L, Larsson A, Svenungsson E, Mohan C, Gunnarsson I. Serum soluble Tumour Necrosis Factor Receptor 2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. Scandinavian Journal of Rheumatology. 2017; 46: 263-272

https://pubmed.ncbi.nlm.nih.gov/27973968/

  • * Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmunity Reviews. 2017; 16: 343–351

https://pubmed.ncbi.nlm.nih.gov/28216072/

  • * Parodis I, Arnaud L, Gerhardsson J, Zickert A, Sundelin B, Malmström V, Svenungsson E, Gunnarsson I. Antiphospholipid Antibodies in Lupus Nephritis. PLoS One. 2016; 11(6): e0158076

https://pubmed.ncbi.nlm.nih.gov/27336701/

  • Zickert A, Oke V, Parodis I, Svenungsson E, Sundström Y, Gunnarsson I. Interferon (IFN)-λ is a potential mediator in lupus nephritis. Lupus Science and Medicine. 2016; 3(1): e000170

https://pubmed.ncbi.nlm.nih.gov/27933198/

  • * Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, Malmström V, Gunnarsson I. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Science and Medicine. 2015; 2: e000061

https://pubmed.ncbi.nlm.nih.gov/25632350/

 

Reviews

Submitted; not yet accepted

  • Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G, Mosca M. Pre-Lupus, Early-Lupus, or undifferentiated connective tissue disease? [Revised manuscript under review]

Published

  • Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020 Feb 18;7(1):e000389. doi: 10.1136/lupus-2020-000389

https://pubmed.ncbi.nlm.nih.gov/32153796/

  • Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon J, Mohan C. Lupus Nephritis. Nature Reviews Disease Primers; 2020; 6:7; doi.org/10.1038/s41572-019-0141-9.

https://pubmed.ncbi.nlm.nih.gov/31974366/

  • Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol. 2020;18(6):549-565. doi: 10.2174/1570161118666191227101636.

https://pubmed.ncbi.nlm.nih.gov/31880245/

  • Parodis I, Dani L, Notarnicola A, Martenhed G, Fernström P, Matikas A, Wiklander OPB. G-CSF-induced aortitis: two cases and review of the literature. Autoimmunity Reviews. 2019; 18(6): 615–620

https://pubmed.ncbi.nlm.nih.gov/30959218/

  • Parodis I, Nikpour M. How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. Annals of the Rheumatic Diseases. 2019; pii: annrheumdis-2019-215650. doi: 10.1136/annrheumdis-2019-215650.

https://pubmed.ncbi.nlm.nih.gov/31076392/

  • Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus. 2013; 22(4): 372-380

https://pubmed.ncbi.nlm.nih.gov/23553780/

  • van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Practice and Research Clinical Rheumatology. 2013; 27(3): 341-349

https://pubmed.ncbi.nlm.nih.gov/24238691/

 

Other scientific works

  • Parodis I, Sjöwall C, Weiner M. [Lupus nephritis] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2020; 4
  • Parodis I. [News about Benlysta] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2019; 3
  • Parodis I, Dani L, Notarnicola A, Martenhed G, Fernström P, Matikas A, Wiklander O. [Drug-induced aortitis] (Article in Swedish). ReumaBulletinen: Swedish Society for Rheumatology. 2019; 1
  • Parodis I. Expert view: Refining the use of belimumab in SLE. 2019 Apr; Hospital Healthcare Europe

http://www.hospitalhealthcare.com/editors-pick/expert-view-refining-use-belimumab-patients-sle

  • Parodis I. [Pharmacological treatment in SLE] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2018; 4
  • Parodis I. Expert view: Ustekinumab for SLE? 2018 Dec; Hospital Healthcare Europe

http://www.hospitalhealthcare.com/editors-pick/expert-view-ustekinumab-sle

  • Parodis I. Optimising management of systemic lupus erythematosus. Hospital Healthcare Europe. 2018; 190-4

https://hospitalhealthcare.com/latest-issue-2018/optimising-management-of-systemic-lupus-erythematosus/

  • Parodis I. [Endocardial thrombi in Behçet’s disease] (Article in Swedish). ReumaBulletinen: Swedish Society for Rheumatology. 2017; 7
  • Parodis I. The latest in lupus, arthritis, and ankylosing spondylitis. Medscape. 2016 Aug.

https://www.medscape.com/viewarticle/867158

  • Parodis I. From Rome, the latest in Rheumatology. Medscape. 2015 Aug.

https://www.medscape.com/viewarticle/849111

  • Parodis I, Gunnarsson I. [Lupus nephritis – where do we stand today?] (Article in Swedish). ReumaBulletinen Vetenskap: Swedish Society for Rheumatology. 2014; 6

Academic honours, awards and prizes

  • 2020 Amgen and Swedish Society of Rheumatology Award/Stipend
  • 2019 Eli Lilly and Swedish Society of Rheumatology Award/Stipend
  • 2019 Pedagogy award for best supervisor of medical students (internal medicine course, MedS, KI)
  • 2019 Winner of the European Lupus Society Training Bursary Programme (of six)
  • 2018 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Exchange programme; chosen participant (of ten)
  • 2014 Pedagogy award for best supervisor of medical students (internal medicine course, MedS, KI)
  • 2007 Prize for best poster, 13th national scientific meeting for med stud and young physicians, Greece
Loading bibliometrics...